---
title: "Biodesix clears key benchmark, hitting 80-plus RS rating"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274013581.md"
description: "Biodesix shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 70 to 84."
datetime: "2026-01-28T15:51:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274013581.md)
  - [en](https://longbridge.com/en/news/274013581.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274013581.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274013581.md) | [繁體中文](https://longbridge.com/zh-HK/news/274013581.md)


# Biodesix clears key benchmark, hitting 80-plus RS rating

Biodesix shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 70 to 84.

### Related Stocks

- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [Biodesix, Inc. (BDSX.US)](https://longbridge.com/en/quote/BDSX.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [iShares Genomics Immnlgy & Hlthcr ETF (IDNA.US)](https://longbridge.com/en/quote/IDNA.US.md)

## Related News & Research

- [Edgewise Therapeutics Completes Key Renal Study for EDG-7500, Setting Up Next Steps for Investors](https://longbridge.com/en/news/278917336.md)
- [Natera Officer Daniel Rabinowitz Sells Shares](https://longbridge.com/en/news/278638753.md)
- [BUZZ-MiNK Therapeutics rises as it wins funding for child cancer cell therapy](https://longbridge.com/en/news/278530484.md)
- [Castle Biosciences study links DecisionDx-Melanoma i31-SLNB low-risk result to 3% sentinel node positivity and 98% three-year recurrence-free survival](https://longbridge.com/en/news/279064627.md)
- [Pulse Biosciences Enrolls First Patient In NPulse Technology Study For Thyroid Microcarcinoma](https://longbridge.com/en/news/279027126.md)